Key Industry Expert Speakers

10th RWE, Market Access, Pricing & Reimbursement Global Congress 2024 Europe

Trends and Strategies to Optimise Value and Patient Access

23rd - 24th May 2024 - Hilton London Kensington, London, UK

Ryotaro Ishikawa, Market Access Head Gene Therapies, Novartis Gene Therapies
Riad Dirani, VP of Global HEOR, Medical Operations & Excellence, Teva
Maarten Van Baelen, Executive Director, Plasma Protein Therapeutics Association
Matthias Heck, Sr Director, International TA Policy Strategy, Alexion Pharmaceuticals
Fabian Schmidt, Global Head, Market Access, HEOR & Policy, Recordati Rare Diseases
Esther Nzenza, Founder and CEO, Decisive Consulting Ltd.
Higia Vassoler, Associate Director - Pricing & Market Access, Red Nucleus
Josie Godfrey, Co-Founder and CEO, Realise Advocacy
Lindsay Birrell, Co- CEO, Realise Advocacy, Chair of trustees, Medics 4 Rare Diseases
Robert Mitchell-Thain, CEO, PBC Foundation
Alexander Bastian, VP, Value & Market Access, AM-Pharma
Kate Learoyd, Campaign Manager, National Society for Phenylketonuria
Saira A. Jan, VP, Chief Pharmacy Officer, Horizon Blue Cross Blue Shield
Nicki K Catterick, Vice President, Global Value and Access Oncology, IPSEN
Eirini Palaka, Vice President, Global Value & Access, Rare Disease, IPSEN
Stefano Romanelli, Senior Government Affairs, EUCOPE
Matias Olsen, Senior Manager, Public Affairs & Policy, EUCOPE
Kirsty Hoyle, CEO, Metabolic Support UK
Girisha Fernando, CEO, Lyfegen HealthTech AG
Sandeep Kiri, Global Head of Health Economics and HTA Evidence, UCB
Hazel Dawson, Market Access Director, UK & Ireland, Alexion Pharma UK
Shaun Rowark, Associate Director for Data Access and Analysis, NICE
And Much More...

Fabian Schmidt

Global Head, Market Access, HEOR & Policy

Recordati Rare Diseases

Fabian Schmidt

Global Head, Market Access, HEOR & Policy

Fabian is a Pharmaceutical Executive with more than 20 years of experience, with a particular focus on the Clinical Development, Health Technology Appraisals (HTA), Pricing and Access to innovative medicines in areas of high unmet medical need. He is the Global Head of Market Access, Health Economics and Outcomes Research and Policy at Recordati Rare Diseases (RRD). In his current role, both the strategic leadership in Pricing, Access and HTA as well as ensuring its execution on a country level has provided him with deep, hands-on experience in a vast array of worldwide markets. Together with affiliates, he works directly with the largest HTA/reimbursement authorities such as NICE, HAS/CEPS and GBA/GKV-SV or PBAC, but also in smaller and medium-sized countries. During his 8 years at RRD, Fabian helped enabling patient access to six innovative medicines across the globe. Prior to RRD, his career in the renowned consultancies Simon-Kucher and EY not only provided him with profound and broad expertise in pharmaceuticals’ pricing, access and HTA. Fabian is also EUCOPE’s deputy representative in the WHO Europe Working Group on Sustainability with the aim to help addressing the challenge of Sustainable Access to Novel Medicines.

Eirini Palaka

Vice President, Global Value & Access, Rare Disease

IPSEN

Eirini Palaka

Vice President, Global Value & Access, Rare Disease

Pharmaceutical industry leader in Commercial and Value & Access, at Global and Local level, with more than 12 years of experience in roles across Sales (specialty and primary care), Account Management, HEOR and Payer Evidence, Market Access and Pricing as well as Healthcare Policy, and a proven track record of successful global blockbuster drug launches with seamless patient access based on robust scientific evidence generation, in Oncology, Rare Disease, Neurology, Immunology and Cardio-Renal.

Nicki K Catterick

Vice President, Global Value and Access Oncology

IPSEN

Nicki K Catterick

Vice President, Global Value and Access Oncology

Over 23 years of experience working across healthcare and the pharmaceutical industry holding a variety of senior leadership positions in Pricing, Value and Access and Commercial, spanning numerous therapy areas including Neuroscience, Respiratory, Immunology and Oncology at both global and local level. With a passion to support and develop teams and people, Nicki is also a Certified and Accredited Personal and Business Coach.

Alexander Bastian

VP, Value & Market Access

AM-Pharma

Alexander Bastian

VP, Value & Market Access

Most recently Alex was Vice President at AM-Pharma, a private dutch biotech company that focused on rare, kidney and critical care diseases. Prior, Alex was Vice President of Value & Market Access at Galapagos NV, a Belgo-Dutch company and Incyte Corporation, an innovative biotechnology company focusing on oncology drug development. Alex previously also led a biotech strategy market access Consulting practice in San Francisco with Bridgehead International after having started his career with industry heavyweights Pfizer (NYC) and Amgen (Switzerland). Alex regularly speaks at conferences and has published papers, posters and abstracts on various pricing, access, and health economic themes, including: The Institute of Medicine National Cancer Policy Forum, The Institute of Medicine’s Health Care Services board, Regional Medicare Caucuses, US State Medical Society Meetings, The American Society of Hematology, ISPOR, the National Venture Capital Association, and The Association of Community Cancer Centers. He current sits on the editorial advisory board for the Journal of Comparative Effectiveness Research. Alex is also currently completing his doctorate in public health at Johns Hopkins University.

Stefano Romanelli

Senior Government Affairs

EUCOPE

Stefano Romanelli

Senior Government Affairs

Stefano works as Senior Government Affairs Manager for EUCOPE, the EU trade associations that represent small and mid-sized companies. He deals with EU policies that cover the EU Pharmaceutical Strategy, recently focussing on the revision of the pharmaceutical legislation and of the OMP Regulation. In addition, his experiences include rare diseases, non-communicable diseases, supply chains and medicine shortages.

Matias Olsen

Senior Manager, Public Affairs & Policy

EUCOPE

Matias Olsen

Senior Manager, Public Affairs & Policy

Matias Olsen is the Senior Manager, Public Affairs and Policy for the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE). Matias supports EUCOPE on key topics, covering among others, implementation of EU HTA, advanced diagnostics, Real-World Evidence, the Patent Package, Europe’s Beating Cancer Plan and relevant market access topics. He coordinates members’ thematic working groups, including the P&R/Market Access Working Group, the Genomics Working Group and the EU HTA Regulation Task Force. Matias has previously advocated on behalf of European cancer patients and worked in the Norwegian Social Security Administration, with reimbursement of medical devices and coordination of social security within the EU/EEA

Lindsay Birrell

Co- CEO, Realise Advocacy, Chair of trustees

Medics 4 Rare Diseases

Lindsay Birrell

Co- CEO, Realise Advocacy, Chair of trustees

>Former CEO of Metabolic Support UK >Chair of trustees at Medics 4 Rare Diseases. >Former member NHS England Metabolic Clinical Reference Group >Patient Advocacy Group experience of UK routes to access >PPV rep on NHSEi Rare disease Advisory Group

Josie Godfrey

JG Zebra Consulting, Co-Founder and CEO

Realise Advocacy

Josie Godfrey

JG Zebra Consulting, Co-Founder and CEO

>Strategic Director, Project HERCULES >Director, JG Zebra Consulting >Former Associate Director, NICE (Highly Specialised Technologies and Topic Selection) >Former Head of Policy, NHS National Specialised Commissioning >International Policy and Patient Advocacy, Sobi

HIGIA VASSOLER

Associate Director - Pricing & Market Access

Red Nucleus

HIGIA VASSOLER

Associate Director - Pricing & Market Access

Esther Nzenza

Founder and CEO

Decisive Consulting Ltd.

Esther Nzenza

Founder and CEO

Esther Nzenza is a seasoned pharmaceutical executive with over 24 years of experience across domestic, regional and international leadership roles. Esther has built and led teams supporting all Commercial Capabilities at an International level, in both Speciality and Rare disease. As the Founder and CEO of Decisive Consulting, Esther specialises in providing the capacity and capability to enable and empower companies at “decisive moments” of their evolution, with a particular focus on Market Access, Capability Development and Commercial Strategy. Blending technical understanding, lived experience and a global network of trusted advisers, Esther and her team can accelerate and focus plans for International commercialisation.

Riad Dirani

VP, Global HEOR, Medical Operations & Excellence

Teva

Riad Dirani

VP, Global HEOR, Medical Operations & Excellence

Riad Dirani, PhD, is currently the VP of Global Health Economic and Outcomes Research and Medical Operations & Excellence at Teva Pharmaceuticals. His responsibilities include overseeing the HEOR, Epidemiology, RWE, Medical Operations, and Medical Communications within Medical Affairs/R&D, and developing and expanding their strategic capabilities optimize the development and commercialization of Teva’s portfolio of products and offerings globally in innovative, generic, and biosimilar medicines. Riad has worked in the pharmaceutical industry since 2000, including positions of increasing responsibility at Aventis, GlaxoSmithKline, Pfizer, and Johnson & Johnson in multiple therapeutic areas. Riad joined Teva in 2014 to build the HEOR group and establish its operating model. Riad received his Ph.D. in Health Services Research/Health Economics from The Pennsylvania State University.

Ryotaro Ishikawa

Global Market Access Director

Novartis

Ryotaro Ishikawa

Global Market Access Director

Ryotaro joined Novartis in 2006 as Brand Manager for Transplantation & Infectious disease in Latin America and rapidly went on to hold several positions of increasing responsibility within the CPO, notably as Specialty Franchise Head and Market Access Head. He then became Regional Pricing & Access Director for the LACan Region, and subsequently moved to Basel to work as Global Market Access Director, Respiratory, currently is the Gene Therapies Head of Access for central European cluster in Novartis. Before joining Novartis, Ryotaro practiced medicine, worked as a payor, to later move into sales in medical devices and renal therapy services. Moreover, he also served in the military with the Multinational Force and Observers - UN, an international peacekeeping force based in the Sinai peninsula. He is an MD, holds both a degree in Hospital Administration and a Master in Business Administration from Universidad de los Andes in Colombia, as well as a postgraduate diploma in Intellectual Property. He has an extensive and unique experience in Commercial, Access, healthcare systems and payor environments,

Maarten Van Baelen

Executive Director

Plasma Protein Therapeutics Association

Maarten Van Baelen

Executive Director

Maarten is the Executive Director of the Plasma Protein Therapeutics Association (PPTA). The PPTA is a dynamic trade association that represents a unique sector of the biologics and biotechnology industry. PPTA represents more than 1.100 human plasma collection centers in North America and Europe, as well as, the manufacturers of lifesaving plasma-derived medicines. PPTA’s mission is, as a trusted partner to health systems, to drive broad and reliable access to plasma protein therapies, with a focus on the well-being of patients and plasma donors. Prior to joining PPTA in 2019, Maarten worked as Market Access Director and Medical Affairs Manager at Medicines for Europe, the trade association representing the European generic, biosimilar and valued added pharmaceutical industries. In addition, during that time, Maarten was advisor to the Board of the European Medicines Verification Organization (EMVO). After graduating as a pharmacist from KU Leuven, Maarten spent several years working in medical affairs roles in the pharmaceutical and medical devices industry, while also being a practicing pharmacist. Maarten also obtained an MBA from the Solvay Brussels School Economics & Management and the École des Ponts Business School in Paris

Matthias Heck

Attorney-at-law, Senior Director, International TA Policy Strategy

Alexion AstraZeneca Rare Disease

Matthias Heck

Attorney-at-law, Senior Director, International TA Policy Strategy

Matthias combines market access expertise from practical experience from funding negotiations across diverse EU markets, including AMNOG, as well as from leading engagement on framework conditions from a policy perspective at national and European levels. Next to company experience, Matthias’ experience includes serving as Head of Brussels office of the German Pharmaceutical Industry Association as well as Legal Counsel of the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE). He has regularly written and spoken on life sciences topics. Matthias is a fully qualified lawyer (Cologne Bar) and holds a Masters in International Economic Relations and Diplomacy (Budapest / St. Gallen).

Robert Mitchell-Thain

CEO

PBC Foundation

Robert Mitchell-Thain

CEO

Robert Mitchell-Thain is a patient advocate of 18 years, with experience in a number of roles, including currently Patient Insights Director at the Global Liver Institute, Vice-Chair of Liver Patients International, the Patient Voice in NHS England’s Hepatobiliary and Pancreas CCG, and was recently leading patient-centred solutions as Head of Education and Development at PBC Foundation. Robert has experience in taking the patient experience and incorporating it into clinical guidelines, abstracts, and journal papers, as well as into every day practice. He has presented at EASL, AASLD and APASL liver-specific conferences. He has also presented to and on behalf of patients in USA, Canada, Israel, China, Japan, Israel, and all over Europe. Robert has led a PBC-specific interactive App which can record GDPR-compliant anonymised data, allowing the patient experience to directly influence industry partners and help them to address unmet need. Using the app data, he presented in poster and orally at a number of national and international scientific conferences. He is currently working with GLI to design and release an interactive patient-driven App that will cover multiple liver diseases, giving patients equitable access to information and the opportunity to be part of the solution in their particular liver disease.

Girisha Fernando

CEO

Lyfegen HealthTech AG

Girisha Fernando

CEO

HAZEL DAWSON

Market Access Director UK & Ireland

Alexion Pharma UK

HAZEL DAWSON

Market Access Director UK & Ireland

Coming Soon!

SANDEEP KIRI

Global Head of Health Economics and HTA Evidence

UCB

SANDEEP KIRI

Global Head of Health Economics and HTA Evidence

Coming Soon!

KATE LEAROYD

Campaign Manager

National Society for Phenylketonuria

KATE LEAROYD

Campaign Manager

Coming Soon!

SAIRA A. JAN

VP, Chief Pharmacy Officer

Horizon Blue Cross Blue Shield

SAIRA A. JAN

VP, Chief Pharmacy Officer

Coming Soon!

KIRSTY HOYLE

CEO

Metabolic Support UK

KIRSTY HOYLE

CEO

Coming Soon!

Omar Ali

Visiting Lecturer Value Based Pricing & Innovative Contracting of New Medicines

University of Portsmouth

Omar Ali

Visiting Lecturer Value Based Pricing & Innovative Contracting of New Medicines

An enthusiastic and well experienced pharmacist with over 20 years comprehensive experience as an NHS Pharmacy Payer [NHS CCGs & Acute Hospitals]. He is confident and innovative, using a well-balanced mastery of skills to achieve goals, maximise potential and bring about shared vision on future landscape for pricing and reimbursement of health technologies. Bridging the gap between payer’s unmet needs and commercial pharma value propositions is his passion. With 9 years experience as an adviser to NICE and a newly appointed role as Visiting Lecturer in Value Based Pricing & Innovative Contracting at the University of Portsmouth, he is well placed to bring expert strategic insights along with access to a powerful National/International Network of Payers within the EU5 managed markets. He has lectured world wide, and recently undertaken PhD doctorate, the thesis entitled “Value Based Pricing & Outcomes Based Innovative Contracting of Medicines”.

SHAUN ROWARK

Associate Director for Data Access and Analysis,

NICE

SHAUN ROWARK

Associate Director for Data Access and Analysis,

Coming Soon!

Rafael Souza, Ph.D

Head of Access Solutions & Pricing, New Markets

BeiGene Switzerland GmbH

Rafael Souza, Ph.D

Head of Access Solutions & Pricing, New Markets

14+ years of experience on Diagnostics and Pharma companies driven by customer needs and market trends. Experience in Science, Sales, Marketing and Access (Pricing, Policy, Evidence, HTA and Strategy) with strengths in Oncology, Immunology, Neuroscience, Rare Diseases, Hemotherapy, Hemophilia and Infectious Disease on Private and Public payer system in Latin America, Middle East, Africa, Europe and Global level.